Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 10/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.39 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.39 |
| ▸ | CACNB1 | Q02641 | 2/20 | 0.39 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3393147 | 0.80 | CACNA2D1 (0.50) | CHRM3CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL4270399 | 0.79 | CHRM3 (0.49) | CHRM3CHRM1CACNA2D1CACNA1BCACNB1 | |
| SCHEMBL4273028 | 0.79 | CACNA2D1 (0.62) | CHRM3CHRM1CACNA2D1CACNA1BCACNB1 | |
| SCHEMBL4278766 | 0.77 | CHRM3 (0.46) | CHRM3CHRM1CACNA2D1CACNA1BCACNB1 | |
| SCHEMBL3397463 | 0.75 | GPR119 (0.50) | CHRM3 | |
| SCHEMBL4278763 | 0.75 | CACNA2D1 (0.47) | CHRM3CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL4279752 | 0.74 | CACNA2D1 (0.66) | CHRM3CHRM1CACNA2D1CACNA1BCACNB1 | |
| SCHEMBL4278107 | 0.71 | KMT2A (0.60) | CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL4278754 | 0.70 | HSD11B1 (0.47) | CHRM3CHRM1 | |
| SCHEMBL3394413 | 0.69 | MEN1 (0.41) | CHRM3CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221603-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-09-03 | — | — | US | claimed |
| EP-1976841-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | Neuromed Pharmaceuticals, Ltd. (CA) | 2008-10-08 | — | — | EP | claimed |
| WO-2007071035-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-06-28 | — | — | WO | claimed |
| US-20090221603-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221603-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | RYR2, CACNA1E, RYR1 | CHRM3 124/4885CHRM1 167/4885CACNA2D1 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.